Effect of immunotherapy or anti-angiogenesis therapy combined with chemotherapy for advanced triple-negative breast cancer: A real-world retrospective study
Among patients with advanced TNBC, ICI-chemo is associated with potentially longer survival compared to anti-angio-chemo as first-line treatment. Given their efficacy and better cost-effectiveness, these two treatment regimens may be considered potentially effective options for second-line therapy and beyond.
Authors
- Qianyi Lu (ORCID: https://orcid.org/0000-0001-5721-0840)
- Hanxing Zhou
- Shusen Wang (ORCID: https://orcid.org/0000-0003-0139-5780)
- Jiajia Huang (ORCID: https://orcid.org/0000-0002-9498-0542)
- Huailiang Wu (ORCID: https://orcid.org/0000-0002-2040-3945)
- Limin Chen (ORCID: https://orcid.org/0000-0002-2107-0441)
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
- State Key Laboratory of Oncology in South China
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2024-11-07
- DOI
- https://doi.org/10.1016/j.intimp.2024.113516
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.42